Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NGEN

NervGen Pharma Corp

1.96

Jul 13 • 11:09AM ET +0.08 (3.99%)

Healthcare Biotechnology Canada Micro NASD

Peers: ACIU AVXL VYGR PRLD DTIL EDIT ARTV RZLT TARA PALI

Scroll to Statements

Index	-
Market Cap	160.68M
Enterprise Value	148.81M
Income	-30.11M
Sales	0.00M
Book/sh	0.05
Cash/sh	0.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Apr 03, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	39.87
P/C	13.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.34
Current Ratio	1.34
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.40
EPS next Y	-0.35
EPS next Q	-0.07
EPS this Y	33.72%
EPS next Y	-20.97%
EPS next 5Y	15.68%
EPS past 3/5Y	-13.03% -10.94%
Sales past 3/5Y	- -
EPS Y/Y TTM	-51.73%
Sales Y/Y TTM	-
EPS Q/Q	60.67%
Sales Q/Q	-
Earnings	May 15 BMO
EPS/Sales Surpr.	80.41% -

Insider Own	22.10%
Insider Trans	0.00%
Inst Own	2.08%
Inst Trans	3.11%
ROA	-232.67%
ROE	-1220.04%
ROIC	-758.33%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.34%
SMA50	-22.95%
SMA200	-44.94%
Trades

Shs Outstand	80.99M
Shs Float	64.18M
Short Float	6.32%
Short Ratio	4.92
Short Interest	4.06M
52W High	6.30 -68.97%
52W Low	1.70 15.00%
Volatility	6.57% 8.30%
ATR (14)	0.17
RSI (14)	41.88
Beta	0.69
Rel Volume	2.60
Avg Volume	824.18K
Volume	623,292

Perf Week	-7.35%
Perf Month	13.01%
Perf Quarter	-51.73%
Perf Half Y	-67.25%
Perf YTD	-65.09%
Perf Year	-32.35%
Perf 3Y	53.94%
Perf 5Y	42.36%
Perf 10Y	-
Recom	1.11
Target Price	10.59
Prev Close	1.88
Price	1.96
Change	3.99%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Leerink Partners	Outperform	$10
Jun-11-26	Initiated	TD Cowen	Buy
Apr-27-26	Initiated	H.C. Wainwright	Buy	$18

May-26-26 07:15AM	NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study (GlobeNewswire)
May-21-26 11:27PM	NervGen Announces Pricing of US$60.0 Million Public Offering of Securities (GlobeNewswire) -43.48%
04:01PM	NervGen Announces Proposed Public Offering of Securities (GlobeNewswire)
May-18-26 07:15AM	NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-27-26 07:30AM	NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer (GlobeNewswire)
07:45AM	Loading…
Apr-13-26 07:45AM	NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-07-26 07:30AM	NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia (GlobeNewswire) -9.57%
Mar-31-26 07:45AM	NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-12-26 04:15PM	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire) -6.98%
Mar-04-26 07:30AM	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs (GlobeNewswire) +8.10%
Feb-18-26 07:30AM	NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-12-26 04:15PM	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire)
Feb-11-26 07:00AM	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium (GlobeNewswire)
Feb-09-26 07:00AM	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury (GlobeNewswire)
Jan-20-26 07:00AM	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing (GlobeNewswire) -6.93%
06:30AM	Loading…
Jan-08-26 06:30AM	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire)

NervGen Pharma Corp. operates as a clinical stage biotech company. It engages in the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

PresidentDr. Adam H. Rogers M.D.

Co-Founder & Independent DirectorDr. Harold Martin Punnett D.M.D.

Chief Medical Advisor & DirectorDr. Randall E. Kaye M.D.

M.D.Dr. Keith A. Vendola M.B.A.

Chief Regulatory Affairs OfficerMs. Shamim Ruff M.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGEN

NervGen Pharma Corp

Upgrade your Finviz experience